Canada Pension Plan Investment Board grew its stake in Intrexon Corp (NYSE:XON) by 23.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 474,400 shares of the biotechnology company’s stock after purchasing an additional 90,400 shares during the period. Canada Pension Plan Investment Board’s holdings in Intrexon were worth $8,169,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of XON. First Trust Advisors LP raised its holdings in Intrexon by 108.7% in the 3rd quarter. First Trust Advisors LP now owns 6,702,226 shares of the biotechnology company’s stock worth $115,412,000 after purchasing an additional 3,491,403 shares in the last quarter. BlackRock Inc. raised its holdings in Intrexon by 76.8% in the 2nd quarter. BlackRock Inc. now owns 4,647,554 shares of the biotechnology company’s stock worth $64,788,000 after purchasing an additional 2,019,142 shares in the last quarter. Northern Trust Corp raised its holdings in Intrexon by 123.1% in the 2nd quarter. Northern Trust Corp now owns 917,510 shares of the biotechnology company’s stock worth $12,791,000 after purchasing an additional 506,186 shares in the last quarter. Frontier Capital Management Co. LLC raised its holdings in Intrexon by 466.3% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 438,693 shares of the biotechnology company’s stock worth $7,554,000 after purchasing an additional 361,232 shares in the last quarter. Finally, Morgan Stanley raised its holdings in Intrexon by 6.7% in the 2nd quarter. Morgan Stanley now owns 3,118,444 shares of the biotechnology company’s stock worth $43,470,000 after purchasing an additional 196,999 shares in the last quarter. Institutional investors and hedge funds own 84.92% of the company’s stock.
Shares of NYSE XON opened at $9.06 on Friday. Intrexon Corp has a 12 month low of $8.92 and a 12 month high of $20.16.
Intrexon (NYSE:XON) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.21). The company had revenue of $32.45 million for the quarter, compared to the consensus estimate of $35.98 million. Intrexon’s quarterly revenue was down 29.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.33) EPS.
Several research analysts have commented on the stock. ValuEngine upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a report on Monday, September 24th. Zacks Investment Research lowered shares of Intrexon from a “buy” rating to a “hold” rating in a report on Monday, October 15th. Finally, JMP Securities upped their price objective on shares of Intrexon from $42.00 to $43.00 and gave the stock a “market outperform” rating in a report on Wednesday, October 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $29.67.
In related news, SVP Joel D. Liffman sold 79,000 shares of the stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $14.59, for a total value of $1,152,610.00. Following the completion of the transaction, the senior vice president now directly owns 79,500 shares in the company, valued at approximately $1,159,905. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 48.20% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/12/08/canada-pension-plan-investment-board-raises-holdings-in-intrexon-corp-xon.html.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Further Reading: What is a Swap?
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NYSE:XON).
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.